Company: SION
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049251
Chunk: 325

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 325
---
 size of our workforce; and

•$1.2 million increase in fees related to the increased use of consultants and professional service organizations.

Interest Income

Interest income increased by $1.1 million to $3.5 million for the three months ended September 30, 2025, from $2.4 million for the three months ended September 30, 2024, primarily driven by an increased investment in debt securities due to the proceeds received from the initial public offering and the amortization of discounts on our investment activity.

Other Income

Other income was $0.1 million and $0.2 million for the three months ended September 30, 2025, and 2024, respectively, due to sublease income in connection with our subleasing agreement.

Comparison of the Nine Months Ended September 30, 2025 and 2024

The following table summarizes our results of operations (in thousands):

Nine Months Ended September 30,Change20252024Operating expenses:Research and development$45,095 $43,035 $2,060 General and administrative20,275 9,388 10,887 Total operating expenses65,370 52,423 12,947 Loss from operations(65,370)(52,423)(12,947)Other income:Interest income10,123 6,051 4,072 Other income419 532 (113)Total other income:10,542 6,583 3,959 Net loss$(54,828)$(45,840)$(8,988)

21

 Research and Development Expenses

The following table summarizes our research and development expenses (in thousands):

Nine Months Ended September 30,Change20252024Direct research and development expenses by program:NBD1 and combination development programs(1)$25,540 $13,588 $11,952 Complementary modulator programs3,813 5,388 (1,575)Unallocated research and development expenses:IPR&D acquisition related costs— 13,639 (13,639)Personnel-related (including stock-based compensation)10,650 6,521 4,129 Other R&D related costs3,294 1,974 1,320 Facility, lab and depreciation1,798 1,925 (127)Total research and development expenses$45,095 $43,035 $2,060 

(1)NBD1 and